Skip to main content
Log in

Screening auf interstitielle Lungenerkrankungen

Sinnhaft oder sinnlos?

Screening for interstitial lung disease

Worthwhile or senseless?

  • Leitthema
  • Published:
Der Pneumologe Aims and scope

Zusammenfassung

Bisher ist ein Screening für interstitielle Lungenerkrankung (ILD) noch nicht etabliert. Da diese Erkrankungsentität jedoch in Anbetracht der steigenden Mortalität immer mehr an Bedeutung gewinnt, sollte eine Implementierung eines solchen Screening diskutiert werden. Sicherlich ist eine Einführung eines computertomographie-(CT-)basierten Screenings speziell nur für ILDs nicht umsetzbar und somit nicht sinnvoll. Stattdessen sollte jeder Kliniker simple Untersuchungsmöglichkeiten adäquat nutzen und ausschöpfen und jedes inspiratorische Knisterrasseln weiterführend abklären. Hier ist sicherlich eine gute Schulung und Sensibilisierung der Kliniker für dieses Krankheitsbild erfolgsversprechend und sollte bereits während des Studiums erfolgen. Falls ein CT-basiertes Lungenkrebsscreening in Deutschland eingeführt wird, könnten die ILDs mitdiagnostiziert werden. Auch CT-morphologische Zufallsbefunde sind abklärungsbedürftig, denn eine frühzeitige Diagnostik kann entscheidende therapeutische Folgen haben und den Verlauf der Erkrankung günstig beeinflussen.

Abstract

Screening for interstitial lung disease (ILD) has not yet been established; however, considering the increasing mortality this disease entity will become increasingly more important and therefore the implementation of screening for ILD should be discussed. It is certainly not possible to introduce a general computed tomography (CT) based screening specifically for interstitial lung diseases. Instead, each clinician should adequately use and exploit the use of simple examination techniques. Thus, every inspiratory crepitation should be further explored. If a CT-based lung cancer screening is implemented in Germany, the CT scan could also be used to screen for ILD. Furthermore, further diagnostics of incidental morphological findings are also necessary as early diagnosis can have decisive therapeutic consequences and possibly also favorably influence the course of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2

Literatur

  1. Akiyama M, Kaneko Y, Yamaoka K et al (2016) Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol Int 36:881–889

    Article  CAS  PubMed  Google Scholar 

  2. Antoniou KM, Symvoulakis EK, Margaritopoulos GA et al (2014) Early diagnosis of IPF: time for a primary-care case-finding initiative? Lancet Respir Med 2:e1

    Article  PubMed  Google Scholar 

  3. Araki T, Putman RK, Hatabu H et al (2016) Development and progression of interstitial lung abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med 194:1514–1522

    Article  PubMed  Google Scholar 

  4. Bach PB, Mirkin JN, Oliver TK et al (2012) Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307:2418–2429

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Behr J, Günther A, Ammenwerth W et al (2013) S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose. Pneumologie 67:81–111

    Article  CAS  PubMed  Google Scholar 

  6. Berliner D, Schneider N, Welte T et al (2016) Differenzialdiagnose bei Luftnot. Dtsch Arztebl Int 113:834–845

    PubMed  PubMed Central  Google Scholar 

  7. Clements PJ, Tashkin D, Roth M et al (2015) The Scleroderma Lung Study II (SLS II) shows that both oral cyclophosphamide (CYC) and mycophenolate mofitil (MMF) are efficacious in treating progressive interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Arthritis Rheumatol 67:1401–1403

    Google Scholar 

  8. Cordier J‑F, Cottin V (2013) Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. Eur Respir J 42:916–923

    Article  PubMed  Google Scholar 

  9. Cottin V, Cordier J‑F (2012) Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 40:519–521

    Article  PubMed  Google Scholar 

  10. Hutchinson J, Fogarty A, Hubbard R et al (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46:795–806

    Article  PubMed  Google Scholar 

  11. Emerging strategies for treatment of systemic sclerosis. Identifier:Nct02597933 CG

  12. Jin GY, Lynch D, Chawla A et al (2013) Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology 268:563–571

    Article  PubMed  PubMed Central  Google Scholar 

  13. Khanna D, Albera C, Fischer A et al (2016) An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol 43(9):1672–1679

    Article  PubMed  Google Scholar 

  14. Kolb M, Richeldi L, Behr J et al (2016) Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. doi:10.1136/thoraxjnl-2016-208710

    PubMed Central  Google Scholar 

  15. Kreuter PDM, Warth A, Wenz H et al (2013) Idiopathische Lungenfibrose. Pneumologe 10:89–97

    Article  Google Scholar 

  16. Ley B, Collard HR, King TE Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183:431–440

    Article  PubMed  Google Scholar 

  17. Mccormack FX, Inoue Y, Moss J et al (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364:1595–1606

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349:1498–1504

    Article  CAS  PubMed  Google Scholar 

  19. Nikolic D, Walsh SL, Fletcher S et al (2016) Validation of A method for automatic detection of lung sounds in Fibrotic interstitial lung disease. C102. Stategies to understand Ild: Registries, prognostic indicators and more. Am Thoracic Soc, S A6231–A6231

    Google Scholar 

  20. Nunes H, Schubel K, Piver D et al (2015) Nonspecific interstitial pneumonia: survival is influenced by the underlying cause. Eur Respir J 45:746–755

    Article  PubMed  Google Scholar 

  21. Salisbury ML, Myers JL, Belloli EA et al (2016) Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go. Am J Respir Crit Care Med. doi:10.1164/rccm.201608-1675PP

  22. The National Lung Screening Trial Research Team (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011:395–409

    Article  Google Scholar 

  23. Winstone TA, Assayag D et al (2014) Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146(2):422–436

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Kreuter.

Ethics declarations

Interessenkonflikt

J. Wälscher und M. Kreuter geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

H. Olschewski, Graz

F. Herth, Heidelberg

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wälscher, J., Kreuter, M. Screening auf interstitielle Lungenerkrankungen. Pneumologe 14, 160–164 (2017). https://doi.org/10.1007/s10405-017-0100-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-017-0100-7

Schlüsselwörter

Keywords

Navigation